Neurocrine Biosciences
NBIX
$97.05
Share price
0.00%
Change (1 day)
3.70%
Change (1 year)
Categories
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.
P/S ratio for Neurocrine Biosciences (NBIX)
P/S ratio as of March 2023 (TTM): 6.30
According to Neurocrine Biosciences 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 6.29667. At the end of 2022 the company had a P/S ratio of 7.71.
P/S ratio history for Neurocrine Biosciences from 2001 to 2022
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2022 | 7.71 | 8.2% |
| 2021 | 7.13 | -16.75% |
| 2020 | 8.56 | -31.97% |
| 2019 | 12.6 | -12.41% |
| 2018 | 14.4 | -66.18% |
| 2017 | 42.5 | -81.05% |
| 2016 | 224 | -9.2% |
| 2015 | 247 | |
| 2014 | N/A | -100% |
| 2013 | 216 | 2204.11% |
| 2012 | 9.35 | 54.16% |
| 2011 | 6.07 | -51.52% |
| 2010 | 12.5 | -69.11% |
| 2009 | 40.5 | 30.41% |
| 2008 | 31.1 | -78.11% |
| 2007 | 142 | 1310.15% |
| 2006 | 10.1 | -46.46% |
| 2005 | 18.8 | -11.08% |
| 2004 | 21.1 | 52.7% |
| 2003 | 13.8 | -82.15% |
| 2002 | 77.6 | 105.49% |
| 2001 | 37.8 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 2.26 | -64.07% | 🇺🇸 USA |
 AbbVie ABBV | 4.79 | -23.97% | 🇺🇸 USA |
 Eli Lilly LLY | 11.2 | 77.31% | 🇺🇸 USA |
 Repligen
RGEN | 11.6 | 83.91% | 🇺🇸 USA |
 Athersys ATHX | 3.82 | -39.34% | 🇺🇸 USA |
 ANI Pharmaceuticals ANIP | 2.12 | -66.30% | 🇺🇸 USA |
 Palatin Technologies PTN | 11.9 | 89.72% | 🇺🇸 USA |
 Royalty Pharma RPRX | 7.42 | 17.81% | 🇬🇧 UK |